Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Chief Financial Officer | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIGAND PHARMACEUTICALS INC
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,696 |
Ending reported balance
After 2026-08-12 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-08-12 · Exercise / conversion · Acquired 16,179 · Balance 43,875 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 2 · 2026-08-12 · Exercise / conversion · Acquired 2,074 · Balance 45,949 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 3 · 2026-08-12 · Exercise / conversion · Acquired 2,869 · Balance 48,818 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 4 · 2026-08-12 · Exercise / conversion · Acquired 7,171 · Balance 55,989 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 5 · 2026-08-12 · Exercise / conversion · Acquired 3,348 · Balance 59,337 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Row 6 · 2026-08-12 · Sale · Disposed 31,641 · Balance 27,696 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.75 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-12 · Exercise / conversion · Disposed 2,869 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F3: The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.22 · Expires 2030-10-01 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-12 · Exercise / conversion · Disposed 7,171 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F4: The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.84 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-12 · Exercise / conversion · Disposed 16,179 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F5: The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.74 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-12 · Exercise / conversion · Disposed 3,348 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F6: The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.04 · Expires 2029-02-01 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-12 · Exercise / conversion · Disposed 2,074 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F7: The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter.
F4: The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter.
F5: The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter.
F6: The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter.
F7: The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,074 | $0.00 Strike: $70.04 | $0.00 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · derivative · entry 11 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,074 shares Expires 2029-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F7 · derivative.exercise_date: The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,348 | $0.00 Strike: $68.74 | $0.00 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · derivative · entry 10 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,348 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F6 · derivative.exercise_date: The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,179 | $0.00 Strike: $52.84 | $0.00 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · derivative · entry 9 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,179 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F5 · derivative.exercise_date: The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,171 | $0.00 Strike: $57.22 | $0.00 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · derivative · entry 8 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,171 shares Expires 2030-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F4 · derivative.exercise_date: The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,869 | $0.00 Strike: $55.75 | $0.00 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · derivative · entry 7 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,869 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 31,641 | $292.07 | $9,241,228.67 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · nonDerivative · entry 6 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,696 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 3,348 | $68.74 | $230,141.52 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · nonDerivative · entry 5 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 7,171 | $57.22 | $410,324.62 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · nonDerivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,869 | $55.75 | $159,946.75 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · nonDerivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,074 | $70.04 | $145,262.96 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 16,179 | $52.84 | $854,898.36 |
DisclosureSEC source: 0002001011-26-000115 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. Read SEC document |
| June 30, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 17 | $160.71 | $2,732.06 |
DisclosureSEC source: 0002001011-26-000107 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,696 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 27, 2026 Filed May 28, 2026 23:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 764 | $0.00 Strike: $63.62 | $0.00 |
DisclosureSEC source: 0002001011-26-000071 · edgardoc.xml · derivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,407 Underlying: Common Stock · 764 shares Expires 2032-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter. Read SEC document |
| May 27, 2026 Filed May 28, 2026 23:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 972 | $0.00 Strike: $52.84 | $0.00 |
DisclosureSEC source: 0002001011-26-000071 · edgardoc.xml · derivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 972 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter. Read SEC document |
| May 27, 2026 Filed May 28, 2026 23:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 972 | $52.84 | $51,360.48 |
DisclosureSEC source: 0002001011-26-000071 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2026 Filed May 28, 2026 23:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 764 | $63.62 | $48,605.68 |
DisclosureSEC source: 0002001011-26-000071 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 23:29 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,405 | $0.00 Strike: $92.65 | $0.00 |
DisclosureSEC source: 0002001011-26-000026 · edgardoc.xml · derivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,405 shares Expires 2028-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 23:29 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,057 | $225.00 | $687,825.00 |
DisclosureSEC source: 0002001011-26-000026 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,010 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 23:29 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,405 | $92.65 | $222,823.25 |
DisclosureSEC source: 0002001011-26-000026 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 466 | $0.00 Strike: $80.72 | $0.00 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · derivative · entry 15 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 466 shares Expires 2026-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F13 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,607 | $0.00 Strike: $58.49 | $0.00 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · derivative · entry 14 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,607 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F13 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,413 | $208.80 | $712,620.75 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 13 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,662 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F12 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $208.3900 to $208.9500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,457 | $207.91 | $510,823.08 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 12 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,075 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F11 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $207.4100 to $208.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,588 | $206.89 | $328,541.96 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 11 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,532 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F10 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $206.4700 to $207.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,457 | $205.79 | $299,841.42 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 10 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,120 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F9 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $205.3700 to $206.3600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 743 | $204.74 | $152,125.46 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 9 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,577 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.4600 to $205.3600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 668 | $203.63 | $136,023.97 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 8 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,320 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $203.4100 to $203.8600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 697 | $202.79 | $141,342.75 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 7 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,988 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.4000 to $203.0500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 950 | $201.73 | $191,640.27 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 6 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,685 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.4600 to $202.3300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 698 | $201.09 | $140,363.54 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 5 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,635 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.5000 to $201.3400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 53 | $200.08 | $10,604.12 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,333 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4400 to $200.0900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 699 | $198.71 | $138,894.93 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,386 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $198.3700 to $199.2500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 466 | $80.72 | $37,615.52 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,607 | $58.49 | $93,993.43 |
DisclosureSEC source: 0002001011-26-000023 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. Read SEC document |
| March 02, 2026 Filed Mar 28, 2026 01:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 23,527 | $0.00 Strike: $202.55 | $0.00 |
DisclosureSEC source: 0002001011-26-000035 · primary_doc.xml · derivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,527 Underlying: Common Stock · 23,527 shares Expires 2036-03-02 F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| March 02, 2026 Filed Mar 28, 2026 01:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 4,933 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000035 · primary_doc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,945 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2027; February 15, 2028; and February 15, 2029, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Pursuant to an election under the Issuer's Nonqualified Deferred Compensation Plan, delivery of shares otherwise issuable upon each vesting date will be deferred. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,270 | $183.83 | $233,464.10 |
DisclosureSEC source: 0002001011-26-000012 · edgardoc.xml · nonDerivative · entry 7 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,012 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,223 | $183.83 | $224,824.09 |
DisclosureSEC source: 0002001011-26-000012 · edgardoc.xml · nonDerivative · entry 6 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,282 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,026 | $183.83 | $188,609.58 |
DisclosureSEC source: 0002001011-26-000012 · edgardoc.xml · nonDerivative · entry 5 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,505 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 4,483 | $183.83 | $824,109.89 |
DisclosureSEC source: 0002001011-26-000012 · edgardoc.xml · nonDerivative · entry 4 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,531 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 8,810 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000012 · edgardoc.xml · nonDerivative · entry 3 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,014 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units ("PSUs"). Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,761 | $183.83 | $691,384.63 |
DisclosureSEC source: 0002001011-26-000012 · edgardoc.xml · nonDerivative · entry 2 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,204 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 7,390 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000012 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,965 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units ("PSUs"). Read SEC document |
| December 31, 2025 Filed Jan 7, 2026 00:21 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 8 | $95.68 | $765.41 |
DisclosureSEC source: 0002001011-26-000003 · edgardoc.xml · nonDerivative · entry 1 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,575 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 181 | $0.00 Strike: $103.42 | $0.00 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · derivative · entry 10 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,186 Underlying: Common Stock · 181 shares Expires 2031-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on January 3, 2025 and as to the remaining on February 3, 2025. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 652 | $0.00 Strike: $92.65 | $0.00 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · derivative · entry 9 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,405 Underlying: Common Stock · 652 shares Expires 2028-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 285 | $0.00 Strike: $63.62 | $0.00 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · derivative · entry 8 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,171 Underlying: Common Stock · 285 shares Expires 2032-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 69 | $0.00 Strike: $57.22 | $0.00 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · derivative · entry 7 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,171 Underlying: Common Stock · 69 shares Expires 2030-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,194 | $0.00 Strike: $52.84 | $0.00 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · derivative · entry 6 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 972 Underlying: Common Stock · 1,194 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 181 | $103.42 | $18,719.02 |
DisclosureSEC source: 0002001011-25-000127 · edgardoc.xml · nonDerivative · entry 5 Espinoza Octavio · CIK 0001905248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.